

OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 6, 2024

I/We	
of	
being the registered holder(s) of (Note 2)	shares of US\$0.0005 each in the share capital of OrbusNeich Medical Group Holdings Limited
(the "Company") hereby appoint the Chairman of t	he annual general meeting of the Company, or (Note 3)
of	

as my/our proxy to attend and vote for me/us and on my/our behalf at the annual general meeting of the Company (the "**Meeting**") to be held at Multi-function Room 2–3, 2/F, Building 17W, Science Park West Avenue, Hong Kong Science Park, Hong Kong on Thursday, June 6, 2024 at 11:00 a.m. and at any adjournment thereof for the purpose of considering and, if thought fit, passing the ordinary resolution as set out in the notice of the Meeting as indicated below or if no such indication is given, as my/our proxy thinks fit and in respect of any other of business that may properly come before the Meeting and/or at any adjournment thereof:

ORDINARY RESOLUTIONS		FOR	AGAINST
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries, and the reports of the directors (the " Director(s) ") and the independent auditor of the Company for the year ended December 31, 2023.		
2.	(a) To re-elect Mr. Ching Chung John CHOW as a non-executive Director.		
	(b) To re-elect Mr. Yip Keung CHAN as an independent non-executive Director.		
	(c) To re-elect Mr. Ka Keung LAU <i>BBS, MH, JP</i> as an independent non-executive Director.		
	(d) To re-elect Dr. Lai Fan Gloria TAM as an independent non-executive Director.		
	(e) To authorize the board of directors (the " Board ") of the Company to fix the Director's remuneration.		
3.	To re-appoint PricewaterhouseCoopers as the auditor of the Company and to authorize the Board to fix its remuneration.		
4.	To approve and declare the payment of a final dividend of HK10 cents per share out of the share premium account of the Company for the year ended December 31, 2023.		
5.	To approve amendments to the terms of the Post-IPO Share Option Scheme.		
6.	(a) To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company not exceeding 20% of the aggregate number of the issued shares.		
	(b) To grant a general mandate to the Directors to repurchase the shares of the Company not exceeding 10% of the aggregate number of issued shares of the Company.		
	SPECIAL RESOLUTION		
7.	To approve amendments to the existing amended and restated articles of association of the Company, and the adoption of the second amended and restated articles of association of the Company.		

(Note 5) Dated this day of 2024 Signature Notes:

3.

Full name(s) and address(es) must be inserted in **BLOCK CAPITALS**. The name of all joint holders should be stated. Please insert the number of shares registered in your name(s) to which the proxy relates. If no number is inserted, this form of proxy will be deemed to relate to all the shares of the Company registered in your name(s). If any proxy other than the Chairman is preferred, please strike out "the Chairman of the annual general meeting of the Company, or" and insert the name and address of the proxy desired in the space provided. ANY ALTERATION MADE TO THIS FORM OF PROXY MUST BE INITIALLED BY THE PERSON(S) WHO SIGN(S) IT, IMPORTANT: IF YOU WISH TO VOTE FOR THE RESOLUTION, TICK THE BOX MARKED "FOR". IF YOU WISH TO VOTE AGAINST", Failure to tick either box will entitle your proxy to cast your ote or abstain at his/her discretion. Your proxy will also be entitled to vote or abstain at his/her discretion on any resolution properly put to the Meeting and/or at any adjournment thereof other than those referred to in the notice convening the Meeting. 4

5

6.

The HE BOX MARKED "AGAINST 1. Particle to the entry one and many presentation of the state of th 7.

8.

9

10.

Your supply of your and your proxy's (or proxies') name(s) and address(es) is on a voluntary basis for the purpose of processing your request for the appointment of a proxy (or proxies) and your your proxy's (or proxies') name(s) and address(es) is on a voluntary basis for the purpose of processing your request for the appointment of a proxy (or proxies) and your your proxy's (or proxies') name(s) and address(es) to our agent, contractor, or third party service provider who provides administrative, computer and other services to us for use in connection with the Purposes and to such parties who are authorized by law to request the information or are otherwise relevant for the Purposes and need to receive the information. Your and your proxy's (or proxies') name(s) and address(es) will be retained for such period as may be necessary to fulfil the Purposes. Request for access to and/or correction of the relevant personal data can be made in accordance with the provisions of the Personal Data (Privacy) Ordinance and any such request should be in writing by mail to the Company.